. The expression levels of TRIM58 mRNA, which were evaluated by qRT-PCR and normalized to GAPDH, are shown relative to those of vehicletreated control cells (means ± SDs of triplicate experiments).
Supplementary Figure S5: (A)
The average β-values (methylation level) of each CpG site targeted in the array-based methylation experiment (see Figure 2A ) in tumors and non-tumorous tissues are shown separately for 12 lung adenocarcinoma (LADC) cases involving six smokers (S) and six non-smokers (NS). CpG sites targeted by pyrosequencing (I-V) are also shown.
(B) The average β-values (methylation level) with standard deviations (vertical bars) of each CpG site targeted in an array-based methylation experiment involving 29 paired tumor and non-tumorous tissue samples from LADC cases obtained from a TCGA data set. *P < 0.05 vs. paired non-tumorous tissue. (C) Correlations between the methylation levels of five CpG sites within the TRIM58 CGI and TRIM58 mRNA expression levels in 17 paired LADC tumor and non-tumorous tissue samples obtained from the TCGA data set. The x-axis represents the β-value (methylation level) of each CpG site determined through an array-based methylation experiment (HumanMethylation450K BeadChip), whereas the y-axis represents the expression levels determined by RNA-seq and quantified by RSEM. Open and closed circles indicate non-tumorous and tumor tissues. Note that tumor and non-tumorous tissues were most clearly separated in cg20429172 and cg26157385, respectively. Roman numerals in parenthesis indicate the pyrosequencing target sites (see Figure 2A ). Differences between methylation levels (β-values) of CpG islands in tumors and paired non-tumorous tissues were assessed by paired t-test. P-values were adjusted with the Benjamini-Hochberg correction (False discovery rate, FDR). The boldface shows P < 0.05. 
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